Physician profile
Song Yu
NPI 1790770352
$345.06
in general payments reported to CMS, 2019-2025
10 companies · $93.45 in 2025
The $93.45 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.48 · 2021: $22.78 · 2022: $36.74 · 2023: $42.33 · 2024: $138 · 2025: $93.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $274.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $148.80 | 2023-2025 | Variax, Dart-Fire, Lpt |
| Integra Lifesciences Corporation | $36.18 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Paratek Pharmaceuticals, INC. | $32.93 | 2024-2025 | Nuzyra |
| Sandoz INC. | $22.60 | 2019-2021 | |
| Treace Medical Concepts, INC. | $20.96 | 2024 | |
| Convatec INC. | $19.00 | 2022 | |
| Kerecis Limited | $18.53 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Bioventus LLC | $17.74 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.66 | 2025 | Jublia |
| Alfasigma USA, INC. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Song Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.